Stock Movers: Novo Nordisk, Vestas, and Babcock Lead European Market Gains

Novo Nordisk's Liver Disease Drug Approval

• 🚀 Novo Nordisk shares surged up to 5% following the US approval of its drug Wegovy for a serious liver disease, MASH.
• 🎯 This approval grants Novo Nordisk access to a significant market before its main competitor, Eli Lilly & Co.
• 💡 The MASH market affects an estimated 6% of US adults, representing approximately 14.9 million people.
• ⚠️ This news provides a crucial boost for Novo Nordisk, which had faced recent setbacks including a 50% year-to-date stock decline and competition from copycat GLP-1 drugs.

Vestas Wind Systems Benefits from Tax Guidance

• 📈 Vestas Wind Systems experienced a significant rise, up to 14%, becoming the biggest mover in European stocks.
• ⚡ The surge is attributed to new, more lenient guidance on tax credits for clean energy projects issued by the US IRS and Treasury Department.
• 🔑 Analysts found these new rules to be more manageable for Vestas than initially feared, providing clarity for wind and solar projects needing to start construction within a year or be placed in service by the end of 2027 to qualify for tax credits.

Babcock Upgraded by RBC

• 💼 Babcock shares increased by up to 2.8% after RBC initiated coverage with an 'outperform' rating.
• 🌟 RBC cited Babcock's strong relationship with the UK Ministry of Defense, its engineering expertise, and a robust management team as key factors for its positive outlook.
• 📊 The company is seen as having an attractive pipeline of opportunities domestically and internationally, and is already outperforming peers in the UK defence sector.
• 🇪🇺 Babcock is also benefiting from a broader rally in the European defense sector, with companies like BAE Systems also seeing gains.